Pfizer to bolster rare disease portfolio with FoldRx acquisition
This article was originally published in Scrip
Executive Summary
Pfizer has reiterated its commitment to developing an orphan and rare diseases franchise by acquiring the private US company FoldRx Pharmaceuticals. The two companies did not disclose the financial terms of the acquisition, though Pfizer will make an upfront payment and further payments depending on the achievement of certain milestones.